Wells Fargo & Company MN Has $8.66 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Wells Fargo & Company MN lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 220,123 shares of the company's stock after buying an additional 17,094 shares during the period. Wells Fargo & Company MN owned approximately 0.26% of CRISPR Therapeutics worth $8,664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Intellectus Partners LLC grew its stake in shares of CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after purchasing an additional 250 shares in the last quarter. Farrow Financial Inc. lifted its holdings in CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after purchasing an additional 270 shares during the period. Kestra Private Wealth Services LLC grew its position in CRISPR Therapeutics by 1.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock valued at $812,000 after buying an additional 310 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in CRISPR Therapeutics by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock valued at $215,000 after buying an additional 372 shares during the period. Finally, Horizon Kinetics Asset Management LLC increased its stake in CRISPR Therapeutics by 4.3% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock valued at $420,000 after buying an additional 443 shares during the period. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

CRSP has been the subject of several recent analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their price target for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Barclays lifted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Stifel Nicolaus cut their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Finally, The Goldman Sachs Group lowered their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Stock Up 3.4 %

Shares of CRSP traded up $1.34 during mid-day trading on Wednesday, reaching $40.57. The company's stock had a trading volume of 454,260 shares, compared to its average volume of 1,630,191. The company has a market cap of $3.50 billion, a price-to-earnings ratio of -9.28 and a beta of 1.85. The business has a fifty day moving average of $40.74 and a 200 day moving average of $43.65. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last three months. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.